Clinical HDAC Inhibitors Are Effective Drugs to Prevent the Entry of SARS-CoV2
Ke Liu, Rongfeng Zou, Wenqiang Cui, Meiqing Li, Xueying Wang, Junlin Dong, Hongchun Li, Hongpei Li, Pei‐Hui Wang, Ximing Shao, Wu Su, H. C. Stephen Chan, Hongchang Li, Shuguang Yuan
Abstract
The outbreak of COVID-19 by the end of 2019 has posed serious health threats to humanity and jeopardized the global economy. However, no effective drugs are available to treat COVID-19 currently and there is a great demand to fight against it. Here, we combined computational screening and an efficient cellular pseudotyped virus system, confirming that clinical HDAC inhibitors can efficiently prevent SARS-CoV-2 and potentially be used to fight against COVID-19.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakOutbreakVirologyMedicineInfectious disease (medical specialty)DiseasePathologyProtein Degradation and InhibitorsHistone Deacetylase Inhibitors ResearchComputational Drug Discovery Methods